tirzepatide formulation WO2024086601A2 - Preserved gip/glp agonist compositions Ozempic® (semaglutide) and Mounjaro™ (tirzepatide),
Description
Regular follow-up appointments provide opportunities to monitor both physical and psychological responses to treatment
A controlled, sustainable ratetypically around 12 pounds per week after the initial phasehelps reduce physiological stress and lowers the risk of hair loss
Tirzepatide resulted in a weight loss of 17.8% (95% CI: 16.3%-19.3%) compared with 12.4% (95% CI: 11.5%-13.4%) for semaglutide
4~73 (3)?
This flexibility is what keeps your treatment working for you
